Axel M. Gressner, Birgit Lahme, Arnfried Brenzel – 1 November 1995 – The activation of proliferation of rat liver hepatic stellate cells (HSC) in cooperation with hepatocytes (PC) was studied using a coculture system and cell‐conditioned media, respectively. The proliferation of HSC was followed by incorporation of [3H] thymidine and BrdU into DNA and by DNA content per culture.
E. Anthony Jones – 1 November 1995
Alan L. Buchman, Mark D. Dubin, Adib A. Moukarzel, Donald J. Jenden, Margareth Roch, Kathleen M. Rice, Jeff Gornbein, Marvin E. Ament – 1 November 1995 – Patients receiving long‐term total parenteral nutrition (TPN) develop hepatic steatosis as a complication. Our previous studies have shown this to be caused, at least in part, by choline deficiency. We studied four patients (1 man, 3 women) aged 50 ± 13 years who had low plasma‐free choline concentrations 4.8 ± 1.7 (normal, 11.4 ± 3.7 nmol/mL). The patients had received TPN for 9.7 ± 4.7 years.
1 November 1995
Philip Y. N. Wong, George Marinos, Mark Peakman, J. Michael Tredger, Johnson Y. N. Lau, Diego Vergani, Nikolai V. Naoumov, Professor Roger Williams – 1 November 1995 – Recurrence of hepatitis B virus (HBV) in the graft is the major problem for patients with chronic HBV infection undergoing liver transplantation, which could be potentiated by the immunosuppression.
Federico G. Villamil, Ke‐Qin Hu, Chang‐Hong Yu, Chao‐Hung Lee, Sergio E. Rojter, Luis G. Podesta, Leonard Makowka, Stephen A. Geller, John M. Vierling – 1 November 1995 – The role of hepatitis C virus (HCV) infection in fulminant hepatic failure is controversial. The frequency of serum HCV RNA positivity in previously reported patients with fulminant hepatic failure (FHF) of indeterminate cause ranged from 0 to 12% in the United States and Europe and from 43% to 59% in Asia.
Catherine M. Pastor, Marie‐Reine Losser, Didier Payen – 1 November 1995 – Controversial studies have been published concerning the role of nitric oxide (NO) release (beneficial or deleterious) during sepsis. Severe hypotension has been treated by NO inhibitors in humans, but animal studies described an increased mortality rate with this treatment. We hypothesized that an NO donor might be beneficial in maintaining liver flow during endotoxemia.
Mitchell L. Shiffman, Lennox Jeffers, Jay H. Hoofnagle, Tommie Sue Tralka – 1 November 1995
W. Kenneth Washburn, W. David Lewis, Roger L. Jenkins – 1 November 1995 – Since January 1994, we have used percutaneous placement of both the subclavian and femoral cannulae to establish access for venovenous bypass during orthotopic liver transplantation. Percutaneous subclavian and femoral cannulae were used in 36 patients of which 5 had portal decompression by placement of a cannula in inferior mesenteric vein percutaneously through the abdominal wall.